TriangleNCT02739594 · OUTCOME
Percentage of Participants With Zoledronate Dose Reduction
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From Baseline to end of study (up to Week 96)
What was measured
The percentage of participants with at least 1 zoledronate dose reduction during the study was reported.
Analysis population: ITT Population; only the Zoledronate arm was included.
Groups in this outcome
Zoledronate
Participants with multiple myeloma received zoledronate via 15-minute IV infusion as 4 mg every 4 weeks for up to 92 weeks. As a result of slow recruitment, the treatment duration was shortened to 40 weeks for participants who had not yet received 48 weeks of treatment. All participants returned for an additional follow-up observation 4 weeks after the end of treatment.
| Group | Source count |
|---|---|
| Zoledronate | 40 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Zoledronate | 30.0 | Not reported | 16.6 | 46.5 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 16.6
- upper Limit
- 46.5
- value
- 30.0
- denoms
- counts
- group Id
- OG000
- value
- 40
- units
- Participants
- description
- The percentage of participants with at least 1 zoledronate dose reduction during the study was reported.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants with multiple myeloma received zoledronate via 15-minute IV infusion as 4 mg every 4 weeks for up to 92 weeks. As a result of slow recruitment, the treatment duration was shortened to 40 weeks for participants who had not yet received 48 weeks of treatment. All participants returned for an additional follow-up observation 4 weeks after the end of treatment.
- id
- OG000
- title
- Zoledronate
- param Type
- NUMBER
- population Description
- ITT Population; only the Zoledronate arm was included.
- reporting Status
- POSTED
- time Frame
- From Baseline to end of study (up to Week 96)
- title
- Percentage of Participants With Zoledronate Dose Reduction
- type
- SECONDARY
- unit Of Measure
- percentage of participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice